PDI Inc. acquired molecular diagnostics company RedPath Integrated Pathology Inc. PDI paid $12mm up front and issued to RedPath shareholders an $11mm non-interest-bearing four-year subordinated note (to be paid in eight equal installments beginning in October 2016). (Nov.)
PDI will incorporate RedPath into its Interpace Diagnostics LLC division, with RedPath eventually taking the Interpace name but retaining...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?